These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7648835)

  • 41. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
    Okhuysen PC; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of YTR 830.
    Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
    Mokaddas EM; Sanyal SC
    J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.
    Collins LA; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1994 Jan; 38(1):144-6. PubMed ID: 8141570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Basic and clinical studies on tazobactam/piperacillin in pediatric field].
    Motohiro T; Nagai K; Yamada T; Oki S; Yamada T; Yoshinaga Y; Tsumura N; Oda K; Sakata Y; Kato H; Imai S; Morita J; Matsuo Y; Ikezawa S; Takahgashi K; Fukuda T; Yamashita Y; Aramaki M; Hayashi M; Yamakawa R; Ono-E ; Tananari Y; Tsutsumi T; Hoshuyama A; Aida K
    Jpn J Antibiot; 1998 Jun; 51(6):413-31. PubMed ID: 9755831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
    Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.